Zydus Lifesciences Sees Sharp Open Interest Surge Amid Rising Market Momentum

Open Interest and Volume Dynamics

On 26 Feb 2026, Zydus Lifesciences recorded an open interest of 17,287 contracts in its derivatives, marking a substantial increase of 2,159 contracts or 14.27% compared to the previous OI of 15,128. This rise in OI was accompanied by a volume of 19,987 contracts, indicating robust trading activity. The futures segment alone accounted for a value of approximately ₹19,235.21 lakhs, while options contributed an overwhelming ₹15,426.14 crores in notional value, culminating in a total derivatives value of ₹22,365.70 lakhs.

This surge in open interest, coupled with elevated volumes, typically reflects fresh positions being established rather than existing ones being squared off. Such a pattern often points to increased conviction among market participants regarding the stock’s near-term direction.

Price Performance and Technical Context

Zydus Lifesciences has outperformed its sector by 1.21% on the day, with the stock gaining 1.44% to close near ₹933. The stock has been on a positive trajectory for two consecutive sessions, delivering a cumulative return of 3.5% over this period. Intraday, it touched a high of ₹947.55, up 3.03%, signalling strong buying interest.

Technically, the stock is trading above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating short to medium-term bullish momentum. However, it remains below the 200-day moving average, suggesting that longer-term resistance levels are yet to be breached. This mixed technical picture may be encouraging traders to position for a potential breakout while remaining cautious of broader trend dynamics.

Investor Participation and Liquidity

Investor participation has notably increased, with delivery volumes on 25 Feb rising to 3.51 lakh shares, a sharp 104.92% increase compared to the five-day average delivery volume. This surge in delivery volume indicates genuine accumulation by investors rather than speculative intraday trading.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹0.97 crore based on 2% of the five-day average traded value. This liquidity profile is favourable for institutional investors and large traders looking to build or unwind positions without significant market impact.

Market Positioning and Directional Bets

The sharp increase in open interest alongside rising volumes suggests that market participants are actively positioning for a directional move in Zydus Lifesciences. Given the stock’s recent outperformance relative to the Pharmaceuticals & Biotechnology sector, traders appear to be leaning towards a bullish stance.

However, the company’s Mojo Score currently stands at 48.0 with a Mojo Grade of Sell, downgraded from Hold on 1 Dec 2025. This rating reflects some caution based on fundamental and technical parameters, despite the recent positive price action. The market cap grade is 2, indicating a mid-cap status with moderate liquidity and volatility characteristics.

Such a divergence between market positioning and fundamental grading may imply that speculative interest is driving the derivatives activity, possibly anticipating near-term catalysts or sector tailwinds. Investors should weigh these factors carefully, considering both the technical momentum and the underlying fundamental outlook.

Sector and Benchmark Comparison

On the day, Zydus Lifesciences delivered a 1.39% return, outperforming the sector’s 0.35% gain and the Sensex’s marginal decline of 0.06%. This relative strength underscores the stock’s appeal amid a broadly mixed market environment. The Pharmaceuticals & Biotechnology sector continues to attract investor interest due to ongoing innovation, regulatory approvals, and export opportunities.

Nevertheless, the stock’s performance must be contextualised within its mid-cap classification and the inherent volatility associated with such companies. Investors should monitor sector trends and broader market cues to gauge sustainability of the current momentum.

Implications for Investors and Traders

The recent surge in open interest and volume in Zydus Lifesciences derivatives highlights a growing interest in the stock’s near-term prospects. For traders, this presents opportunities to capitalise on momentum-driven moves, especially given the stock’s technical positioning above key moving averages and relative outperformance.

Long-term investors, however, should remain cautious due to the current Mojo Grade of Sell and the stock’s position below the 200-day moving average. It is advisable to monitor upcoming quarterly results, regulatory developments, and sector dynamics before committing additional capital.

Furthermore, the elevated options notional value suggests that hedging activity or speculative option strategies may be influencing price action. This complexity underscores the importance of a nuanced approach to trading and investment decisions in Zydus Lifesciences.

Outlook and Conclusion

Zydus Lifesciences is currently at a crossroads where technical momentum and market positioning are signalling potential upside, while fundamental assessments urge prudence. The open interest surge in derivatives is a clear indicator of increased market focus, possibly anticipating positive news flow or sector tailwinds.

Investors should closely track volume and open interest trends alongside price action to discern whether this activity translates into sustained gains or a short-lived speculative spike. Given the stock’s mid-cap status and sector volatility, a balanced approach combining technical signals with fundamental analysis remains essential.

In summary, the derivatives market activity in Zydus Lifesciences reflects a growing bullish sentiment, but the underlying fundamentals and longer-term technical indicators counsel measured optimism. Market participants are advised to stay vigilant and adapt strategies as new data emerges.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today